Evanson Asset Management LLC raised its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 23.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,832 shares of the medical research company’s stock after buying an additional 345 shares during the quarter. Evanson Asset Management LLC’s holdings in Amgen were worth $318,000 as of its most recent SEC filing.
Several other hedge funds have also modified their holdings of the company. Swiss National Bank raised its stake in shares of Amgen by 2.1% in the second quarter. Swiss National Bank now owns 2,690,908 shares of the medical research company’s stock valued at $463,455,000 after purchasing an additional 54,900 shares in the last quarter. Delta Lloyd Asset Management N.V. acquired a new position in shares of Amgen in the second quarter valued at $13,728,000. Artemis Investment Management LLP raised its stake in shares of Amgen by 168.7% in the second quarter. Artemis Investment Management LLP now owns 139,877 shares of the medical research company’s stock valued at $24,090,000 after purchasing an additional 87,822 shares in the last quarter. Hikari Power Ltd raised its stake in shares of Amgen by 2.9% in the second quarter. Hikari Power Ltd now owns 42,700 shares of the medical research company’s stock valued at $7,354,000 after purchasing an additional 1,200 shares in the last quarter. Finally, Oppenheimer & Co. Inc. raised its stake in shares of Amgen by 5.5% in the second quarter. Oppenheimer & Co. Inc. now owns 171,548 shares of the medical research company’s stock valued at $29,546,000 after purchasing an additional 8,888 shares in the last quarter. Institutional investors own 79.50% of the company’s stock.
Shares of Amgen, Inc. (NASDAQ:AMGN) opened at $182.55 on Tuesday. The company has a debt-to-equity ratio of 1.35, a quick ratio of 5.17 and a current ratio of 5.49. The company has a market capitalization of $135,638.63, a price-to-earnings ratio of 71.03, a PEG ratio of 2.31 and a beta of 1.37. Amgen, Inc. has a 1-year low of $152.16 and a 1-year high of $201.23.
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 8th. Stockholders of record on Thursday, May 17th will be issued a dividend of $1.32 per share. This represents a $5.28 annualized dividend and a dividend yield of 2.89%. The ex-dividend date of this dividend is Wednesday, May 16th. Amgen’s payout ratio is presently 205.45%.
Amgen announced that its Board of Directors has approved a stock repurchase program on Thursday, February 1st that allows the company to buyback $10.00 billion in outstanding shares. This buyback authorization allows the medical research company to buy shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its shares are undervalued.
A number of research analysts recently commented on the company. Argus upgraded Amgen from a “hold” rating to a “buy” rating and upped their target price for the company from $192.33 to $220.00 in a research note on Tuesday, January 23rd. Royal Bank of Canada restated a “hold” rating and issued a $189.00 target price on shares of Amgen in a research note on Wednesday, January 24th. JPMorgan Chase & Co. upped their target price on Amgen from $184.00 to $189.00 and gave the company a “neutral” rating in a research note on Wednesday, January 24th. Vetr lowered Amgen from a “hold” rating to a “sell” rating and set a $181.60 target price for the company. in a research note on Tuesday, March 6th. Finally, BMO Capital Markets upped their target price on Amgen from $192.00 to $202.00 and gave the company a “market perform” rating in a research note on Friday, February 2nd. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $191.72.
In other news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $185.62, for a total transaction of $283,070.50. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders have sold 4,575 shares of company stock worth $838,064 in the last 90 days. Company insiders own 0.19% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Amgen, Inc. (AMGN) Shares Bought by Evanson Asset Management LLC” was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://stocknewstimes.com/2018/03/20/amgen-inc-amgn-shares-bought-by-evanson-asset-management-llc.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.